NeuroVive Pharmaceutical ABの内部者の所有権

NeuroVive Pharmaceutical ABの内部者の所有権は何ですか。

NeuroVive Pharmaceutical ABの内部者の所有権は4.31%です。

内部者の所有権の定義は何ですか。



管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー(5%超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

OTCのセクタHealth Careにおける内部者の所有権の企業と比べるNeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical ABは何をしますか。

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

NeuroVive Pharmaceutical ABと類似の内部者の所有権